Jonathan Sockolosky, PhD

Senior Director, CSO Partner Team at Curie.Bio

Speaker

Jonathan Sockolosky is currently a Senior Director on the CSO Partner Team at Curie.Bio, a founder-centric, seed stage venture firm coupled with an industry-grade biotech accelerator. Jonathan's role on the CSO-P Team is to drive investment decisions, company strategy, and execution by supporting founders as their drug discovery co-pilot from concept to Series A. Prior to joining Curie.Bio, Jonathan was a Principal Scientist in the Department of Antibody Engineering at Genentech where he led the development of next generation immune modulating therapeutics for oncology and cancer immunology, with a focus on cytokine biology and engineering. Prior to Genentech, Jonathan was a Principal Scientist at ALX Oncology, a clinical stage biotechnology company developing CD47/SIRPa antagonists for cancer immunotherapy. Jonathan received his BS/MS in Biomedical Engineering from the University of Michigan, PhD in Pharmaceutical Sciences from UCSF, and completed postdoctoral research at Stanford where he discovered and developed orthogonal IL-2 cytokine-receptor pairs for cell therapy currently under clinical development by Synthekine.